- Frencken (SGX:E28)’s 1H23 revenue fell 9.7% y-o-y to S$351.0m, as revenue in its business segments declined y-o-y, with the exception of its medical, as well as analytical and life sciences segments. Frencken saw lower transport and freight expenses, as well as lower staff-related expenses in 1H23.
- - Read this at SGinvestors.io -
- In our view, Frencken managed to perform better q-o-q in 2Q23, with revenue up 3.5% and net profit up 27.7%. Gross profit margin was stable q-o-q at 12.4% in 2Q23 (vs. 12.3% in 1Q23).
- - Read this at SGinvestors.io -
2H23F revenue expected to remain stable h-o-h
- While Frencken remains cautious on its FY23F outlook, it expects revenue to be stable in 2H23 vs 1H23.
- For 2H23F, Frencken has provided the following guidance for its segmental revenue:
- Read more at SGinvestors.io.
Above is the excerpt from research report by CGS-CIMB.
Clients of CGS-CIMB may access the full report in PDF @ https://www.itradecimb.com.sg/.
William TNG CFA CGS-CIMB Research | https://www.cgs-cimb.com 2023-08-18
Read also CGS-CIMB's most recent report:
2023-11-23 Frencken - Most Segments’ Revenue To Grow In 2H23.Previous report by CGS-CIMB:
2023-10-19 Frencken Group - FY24-25F Outlook Likely To Improve.Price targets by 4 other brokers at Frencken Target Prices.
Listing of research reports at Frencken Analyst Reports.
Relevant links:
Frencken Share Price History,
Frencken Announcements,
Frencken Dividends & Corporate Actions,
Frencken News Articles
